Tempus ECG-AF vs OPTIS Mobile Next Imaging
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your objective is to proactively identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months, facilitating earlier intervention and management strategies. This tool is specifically designed for screening eligible older adults using existing 12-lead ECG data to support preventative cardiology efforts.
View Tempus ECG-AF →Choose OPTIS Mobile Next Imaging if…
Choose OPTIS Mobile Next Imaging if you need an AI-powered, transportable system to provide real-time, high-resolution Optical Coherence Tomography (OCT) and coronary physiology measurements during percutaneous coronary intervention (PCI) procedures. This system is ideal for cath labs seeking to enhance procedural guidance, optimize stent placement, and improve decision-making during complex coronary interventions.
View OPTIS Mobile Next Imaging →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | OPTIS Mobile Next Imaging |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | On-premise (mobile cart system integrated into catheterization laboratories) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
OPTIS Mobile Next ImagingTool B, the OPTIS Mobile Next Imaging System, offers explicit features designed for enhanced usability in a cath lab environment, such as a wireless tableside controller and rapid image processing. While Tool A integrates into existing systems, Tool B's dedicated hardware and workflow optimizations suggest a more tailored and efficient user experience for its specific application.
Clinical Value
OPTIS Mobile Next ImagingTool B provides real-time, high-resolution imaging and physiological measurements directly guiding percutaneous coronary intervention (PCI) procedures, offering immediate and critical impact on interventional decision-making and procedural success. Tool A provides valuable predictive risk assessment for AF, but Tool B's direct influence on an ongoing invasive procedure offers a more immediate and tangible clinical benefit during a critical intervention.
Pricing & Value
Tempus ECG-AFTool A clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing transparency and a clear financial value proposition for healthcare providers. Tool B's pricing information is not disclosed in the provided facts, making it impossible to assess its financial value or cost-effectiveness.
Enterprise Readiness
Tempus ECG-AFTool A explicitly states 'yes' for both BAA and HIPAA compliance, along with FDA clearance and integration into healthcare facility systems. Tool B's BAA status is not explicitly stated for the device itself, and HIPAA compliance is described as 'likely,' which offers less direct assurance from the vendor compared to Tool A's explicit declarations.
Innovation
OPTIS Mobile Next ImagingTool B integrates a broader range of advanced technologies, including AI, Optical Coherence Tomography (OCT), coronary physiology measurements (RFR/FFR), wireless control, and simultaneous angio/OCT co-registration, into a single mobile platform for real-time interventional guidance. While Tool A's predictive AI for ECGs is innovative, Tool B's convergence of multiple high-tech modalities for immediate procedural application represents a higher degree of technological integration and novel workflow enhancement.
Support & Docs
TieNeither the structured facts nor readily available public information provide specific details regarding the support services or documentation for either Tempus ECG-AF or OPTIS Mobile Next Imaging. Without product-specific information to compare, it is not possible to distinguish between the two on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | OPTIS Mobile Next Imaging |
|---|---|---|
| Name | Tempus ECG-AF | OPTIS Mobile Next Imaging |
| Company | Tempus AI, Inc. | Abbott Medical |
| Primary Purpose | AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | AI-powered, transportable intravascular imaging system for cath labs, offering high-resolution OCT and coronary physiology measurements to guide PCI procedures. |
| Target Patient/Procedure | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for earlier identification of AF. | Patients undergoing PCI procedures, for informed decision-making. |
| Core Technology/Analysis | AI-based algorithm for 12-lead ECG analysis. | AI-powered Optical Coherence Tomography (OCT) intravascular imaging and coronary physiology measurements (RFR/FFR). |
| Specialties Supported | Cardiology, Geriatrics, Internal Medicine | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and OPTIS Mobile Next Imaging.
More Comparisons
More matchups featuring Tempus ECG-AF or OPTIS Mobile Next Imaging
Backers
Who funded each tool's parent company.